British Journal of Clinical Pharmacology

Cover image for Vol. 83 Issue 2

February 2017

Volume 83, Issue 2

Pages 217–436

  1. ISSUE INFORMATION

    1. Top of page
    2. ISSUE INFORMATION
    3. ISSUE HIGHLIGHTS
    4. EDITORIAL
    5. COMMENTARY
    6. SYSTEMATIC REVIEW
    7. REVIEWS
    8. CLINICAL TRIALS
    9. TRANSLATIONAL RESEARCH
    10. PHARMACOKINETICS
    11. DRUG INTERACTIONS
    12. THERAPEUTICS
    13. DRUG SAFETY
    14. PHARMACOEPIDEMIOLOGY
    15. LETTER TO THE EDITOR
    16. ERRATUM
    1. You have free access to this content
      Issue Information (pages 217–218)

      Version of Record online: 16 JAN 2017 | DOI: 10.1111/bcp.13106

  2. ISSUE HIGHLIGHTS

    1. Top of page
    2. ISSUE INFORMATION
    3. ISSUE HIGHLIGHTS
    4. EDITORIAL
    5. COMMENTARY
    6. SYSTEMATIC REVIEW
    7. REVIEWS
    8. CLINICAL TRIALS
    9. TRANSLATIONAL RESEARCH
    10. PHARMACOKINETICS
    11. DRUG INTERACTIONS
    12. THERAPEUTICS
    13. DRUG SAFETY
    14. PHARMACOEPIDEMIOLOGY
    15. LETTER TO THE EDITOR
    16. ERRATUM
    1. You have free access to this content
      Issue highlights (pages 219–220)

      Version of Record online: 16 JAN 2017 | DOI: 10.1111/bcp.13209

  3. EDITORIAL

    1. Top of page
    2. ISSUE INFORMATION
    3. ISSUE HIGHLIGHTS
    4. EDITORIAL
    5. COMMENTARY
    6. SYSTEMATIC REVIEW
    7. REVIEWS
    8. CLINICAL TRIALS
    9. TRANSLATIONAL RESEARCH
    10. PHARMACOKINETICS
    11. DRUG INTERACTIONS
    12. THERAPEUTICS
    13. DRUG SAFETY
    14. PHARMACOEPIDEMIOLOGY
    15. LETTER TO THE EDITOR
    16. ERRATUM
    1. You have free access to this content
  4. COMMENTARY

    1. Top of page
    2. ISSUE INFORMATION
    3. ISSUE HIGHLIGHTS
    4. EDITORIAL
    5. COMMENTARY
    6. SYSTEMATIC REVIEW
    7. REVIEWS
    8. CLINICAL TRIALS
    9. TRANSLATIONAL RESEARCH
    10. PHARMACOKINETICS
    11. DRUG INTERACTIONS
    12. THERAPEUTICS
    13. DRUG SAFETY
    14. PHARMACOEPIDEMIOLOGY
    15. LETTER TO THE EDITOR
    16. ERRATUM
    1. Poor reporting and documentation in drug-associated Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis – Lessons for medication safety (pages 224–226)

      Caitlin Goldblatt, Sharmila Khumra, Jane Booth, Karen Urbancic, M. Lindsay Grayson and Jason A. Trubiano

      Version of Record online: 4 OCT 2016 | DOI: 10.1111/bcp.13103

      • image
  5. SYSTEMATIC REVIEW

    1. Top of page
    2. ISSUE INFORMATION
    3. ISSUE HIGHLIGHTS
    4. EDITORIAL
    5. COMMENTARY
    6. SYSTEMATIC REVIEW
    7. REVIEWS
    8. CLINICAL TRIALS
    9. TRANSLATIONAL RESEARCH
    10. PHARMACOKINETICS
    11. DRUG INTERACTIONS
    12. THERAPEUTICS
    13. DRUG SAFETY
    14. PHARMACOEPIDEMIOLOGY
    15. LETTER TO THE EDITOR
    16. ERRATUM
    1. You have free access to this content
      The value of patient reporting to the pharmacovigilance system: a systematic review (pages 227–246)

      Pedro Inácio, Afonso Cavaco and Marja Airaksinen

      Version of Record online: 12 OCT 2016 | DOI: 10.1111/bcp.13098

      • image
  6. REVIEWS

    1. Top of page
    2. ISSUE INFORMATION
    3. ISSUE HIGHLIGHTS
    4. EDITORIAL
    5. COMMENTARY
    6. SYSTEMATIC REVIEW
    7. REVIEWS
    8. CLINICAL TRIALS
    9. TRANSLATIONAL RESEARCH
    10. PHARMACOKINETICS
    11. DRUG INTERACTIONS
    12. THERAPEUTICS
    13. DRUG SAFETY
    14. PHARMACOEPIDEMIOLOGY
    15. LETTER TO THE EDITOR
    16. ERRATUM
    1. You have full text access to this OnlineOpen article
    2. You have free access to this content
    3. You have free access to this content
      Managing drug–drug interactions with new direct-acting antiviral agents in chronic hepatitis C (pages 269–293)

      Sarah Talavera Pons, Anne Boyer, Geraldine Lamblin, Philip Chennell, François-Thibault Châtenet, Carine Nicolas, Valérie Sautou and Armand Abergel

      Version of Record online: 26 OCT 2016 | DOI: 10.1111/bcp.13095

      • image
    4. You have free access to this content
      A review of factors explaining variability in fentanyl pharmacokinetics; focus on implications for cancer patients (pages 294–313)

      Evelien J. M. Kuip, Maarten L. Zandvliet, Stijn L. W. Koolen, Ron H. J. Mathijssen and Carin C. D. van der Rijt

      Version of Record online: 29 OCT 2016 | DOI: 10.1111/bcp.13129

      • image
      • image
  7. CLINICAL TRIALS

    1. Top of page
    2. ISSUE INFORMATION
    3. ISSUE HIGHLIGHTS
    4. EDITORIAL
    5. COMMENTARY
    6. SYSTEMATIC REVIEW
    7. REVIEWS
    8. CLINICAL TRIALS
    9. TRANSLATIONAL RESEARCH
    10. PHARMACOKINETICS
    11. DRUG INTERACTIONS
    12. THERAPEUTICS
    13. DRUG SAFETY
    14. PHARMACOEPIDEMIOLOGY
    15. LETTER TO THE EDITOR
    16. ERRATUM
    1. Population pharmacokinetics and analgesic potency of oxycodone (pages 314–325)

      Byung-Moon Choi, Yong-Hun Lee, Sang-Mee An, Soo-Han Lee, Eun-Kyung Lee and Gyu-Jeong Noh

      Version of Record online: 29 SEP 2016 | DOI: 10.1111/bcp.13101

      • image
      • image
      • image
      • image
      • image
    2. You have free access to this content
      Pharmacokinetics and pharmacodynamics of PF-05190457: The first oral ghrelin receptor inverse agonist to be profiled in healthy subjects (pages 326–338)

      William S. Denney, Gabriele E. Sonnenberg, Santos Carvajal-Gonzalez, Theresa Tuthill and V. Margaret Jackson

      Version of Record online: 29 OCT 2016 | DOI: 10.1111/bcp.13127

      • image
      • image
      • image
      • image
    3. You have full text access to this OnlineOpen article
      Thorough QT study of the effect of intravenous amisulpride on QTc interval in Caucasian and Japanese healthy subjects (pages 339–348)

      Jörg Täubel, Georg Ferber, Gabriel Fox, Sara Fernandes, Ulrike Lorch and A. John Camm

      Version of Record online: 21 OCT 2016 | DOI: 10.1111/bcp.13128

      • image
      • image
      • image
  8. TRANSLATIONAL RESEARCH

    1. Top of page
    2. ISSUE INFORMATION
    3. ISSUE HIGHLIGHTS
    4. EDITORIAL
    5. COMMENTARY
    6. SYSTEMATIC REVIEW
    7. REVIEWS
    8. CLINICAL TRIALS
    9. TRANSLATIONAL RESEARCH
    10. PHARMACOKINETICS
    11. DRUG INTERACTIONS
    12. THERAPEUTICS
    13. DRUG SAFETY
    14. PHARMACOEPIDEMIOLOGY
    15. LETTER TO THE EDITOR
    16. ERRATUM
    1. You have free access to this content
      Translating QT interval prolongation from conscious dogs to humans (pages 349–362)

      Vincent F. S. Dubois, Giovanni Smania, Huixin Yu, Ramona Graf, Anne S. Y. Chain, Meindert Danhof, Oscar Della Pasqua, on behalf of the Cardiovascular Safety Project Team and TI Pharma PKPD Platform

      Version of Record online: 29 OCT 2016 | DOI: 10.1111/bcp.13123

      • image
      • image
      • image
      • image
      • image
  9. PHARMACOKINETICS

    1. Top of page
    2. ISSUE INFORMATION
    3. ISSUE HIGHLIGHTS
    4. EDITORIAL
    5. COMMENTARY
    6. SYSTEMATIC REVIEW
    7. REVIEWS
    8. CLINICAL TRIALS
    9. TRANSLATIONAL RESEARCH
    10. PHARMACOKINETICS
    11. DRUG INTERACTIONS
    12. THERAPEUTICS
    13. DRUG SAFETY
    14. PHARMACOEPIDEMIOLOGY
    15. LETTER TO THE EDITOR
    16. ERRATUM
  10. DRUG INTERACTIONS

    1. Top of page
    2. ISSUE INFORMATION
    3. ISSUE HIGHLIGHTS
    4. EDITORIAL
    5. COMMENTARY
    6. SYSTEMATIC REVIEW
    7. REVIEWS
    8. CLINICAL TRIALS
    9. TRANSLATIONAL RESEARCH
    10. PHARMACOKINETICS
    11. DRUG INTERACTIONS
    12. THERAPEUTICS
    13. DRUG SAFETY
    14. PHARMACOEPIDEMIOLOGY
    15. LETTER TO THE EDITOR
    16. ERRATUM
    1. Use of a cocktail probe to assess potential drug interactions with cytochrome P450 after administration of belatacept, a costimulatory immunomodulator (pages 370–380)

      Daphne Williams, Xiaolu Tao, Lili Zhu, Michele Stonier, Justin D. Lutz, Eric Masson, Sean Zhang, Bishu Ganguly, Zoe Tzogas, Susan Lubin and Bindu Murthy

      Version of Record online: 2 NOV 2016 | DOI: 10.1111/bcp.13097

      • image
      • image
      • image
    2. An S-warfarin and AZD1981 interaction: in vitro and clinical pilot data suggest the N-deacetylated amino acid metabolite as the primary perpetrator (pages 381–392)

      Ken Grime, Rikard Pehrson, Pär Nordell, Michael Gillen, Wolfgang Kühn, Timothy Mant, Marie Brännström, Petter Svanberg, Barry Jones and Clive Brealey

      Version of Record online: 13 OCT 2016 | DOI: 10.1111/bcp.13102

      • image
      • image
      • image
      • image
      • image
      • image
      • image
  11. THERAPEUTICS

    1. Top of page
    2. ISSUE INFORMATION
    3. ISSUE HIGHLIGHTS
    4. EDITORIAL
    5. COMMENTARY
    6. SYSTEMATIC REVIEW
    7. REVIEWS
    8. CLINICAL TRIALS
    9. TRANSLATIONAL RESEARCH
    10. PHARMACOKINETICS
    11. DRUG INTERACTIONS
    12. THERAPEUTICS
    13. DRUG SAFETY
    14. PHARMACOEPIDEMIOLOGY
    15. LETTER TO THE EDITOR
    16. ERRATUM
    1. An assessment of the variation in the concentration of acetylcysteine in infusions for the treatment of paracetamol overdose (pages 393–399)

      George P. Bailey, David M. Wood, John R. H. Archer, Edmund Rab, Robert J. Flanagan and Paul I. Dargan

      Version of Record online: 29 SEP 2016 | DOI: 10.1111/bcp.13099

      • image
      • image
  12. DRUG SAFETY

    1. Top of page
    2. ISSUE INFORMATION
    3. ISSUE HIGHLIGHTS
    4. EDITORIAL
    5. COMMENTARY
    6. SYSTEMATIC REVIEW
    7. REVIEWS
    8. CLINICAL TRIALS
    9. TRANSLATIONAL RESEARCH
    10. PHARMACOKINETICS
    11. DRUG INTERACTIONS
    12. THERAPEUTICS
    13. DRUG SAFETY
    14. PHARMACOEPIDEMIOLOGY
    15. LETTER TO THE EDITOR
    16. ERRATUM
    1. Eosinophilic drug reactions detected by a prospective pharmacovigilance programme in a tertiary hospital (pages 400–415)

      Elena Ramírez, Nicolás Medrano-Casique, Hoi Y. Tong, Teresa Bellón, Rosario Cabañas, Ana Fiandor, Jessica González-Ramos, Pedro Herranz, Elena Trigo, Mario Muñoz, Alberto M. Borobia, Antonio J. Carcas and Jesús Frías

      Version of Record online: 12 OCT 2016 | DOI: 10.1111/bcp.13096

      • image
      • image
  13. PHARMACOEPIDEMIOLOGY

    1. Top of page
    2. ISSUE INFORMATION
    3. ISSUE HIGHLIGHTS
    4. EDITORIAL
    5. COMMENTARY
    6. SYSTEMATIC REVIEW
    7. REVIEWS
    8. CLINICAL TRIALS
    9. TRANSLATIONAL RESEARCH
    10. PHARMACOKINETICS
    11. DRUG INTERACTIONS
    12. THERAPEUTICS
    13. DRUG SAFETY
    14. PHARMACOEPIDEMIOLOGY
    15. LETTER TO THE EDITOR
    16. ERRATUM
  14. LETTER TO THE EDITOR

    1. Top of page
    2. ISSUE INFORMATION
    3. ISSUE HIGHLIGHTS
    4. EDITORIAL
    5. COMMENTARY
    6. SYSTEMATIC REVIEW
    7. REVIEWS
    8. CLINICAL TRIALS
    9. TRANSLATIONAL RESEARCH
    10. PHARMACOKINETICS
    11. DRUG INTERACTIONS
    12. THERAPEUTICS
    13. DRUG SAFETY
    14. PHARMACOEPIDEMIOLOGY
    15. LETTER TO THE EDITOR
    16. ERRATUM
    1. Chemical gastritis and colitis related to hydrogen peroxide mouthwash (pages 427–428)

      Magda Zanelli, Moira Ragazzi and Loredana De Marco

      Version of Record online: 30 SEP 2016 | DOI: 10.1111/bcp.13100

    2. Contraindicated use of 5-alpha-reductase inhibitors in women (pages 429–431)

      Martina Teichert, Eugene van Puijenbroek and Bruno H. Stricker

      Version of Record online: 30 SEP 2016 | DOI: 10.1111/bcp.13118

      • image
    3. Endpoints in strategies to reduce polypharmacy (pages 432–433)

      Andrés Gaviria-Mendoza, Jorge Enrique Machado-Alba, Juan Pablo Castaño-Montoya, Manuel Enrique Machado-Duque and Claudia Giraldo-Giraldo

      Version of Record online: 29 SEP 2016 | DOI: 10.1111/bcp.13122

    4. Reply to ‘Endpoints in strategies to reduce polypharmacy’ (page 434)

      Tim Johansson, Maria Flamm and Andreas Sönnichsen

      Version of Record online: 4 OCT 2016 | DOI: 10.1111/bcp.13125

    5. Discrepancies in paper by Chiam et al.: The haemodynamic effects of intravenous paracetamol (page 435)

      Tone Westergren and Karen Astrid Boldingh Debernard

      Version of Record online: 16 JAN 2017 | DOI: 10.1111/bcp.13182

  15. ERRATUM

    1. Top of page
    2. ISSUE INFORMATION
    3. ISSUE HIGHLIGHTS
    4. EDITORIAL
    5. COMMENTARY
    6. SYSTEMATIC REVIEW
    7. REVIEWS
    8. CLINICAL TRIALS
    9. TRANSLATIONAL RESEARCH
    10. PHARMACOKINETICS
    11. DRUG INTERACTIONS
    12. THERAPEUTICS
    13. DRUG SAFETY
    14. PHARMACOEPIDEMIOLOGY
    15. LETTER TO THE EDITOR
    16. ERRATUM
    1. You have free access to this content
      Erratum (page 436)

      Version of Record online: 16 JAN 2017 | DOI: 10.1111/bcp.13187

SEARCH

SEARCH BY CITATION